RLMD Relmada Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why RLMD matters now
Relmada Therapeutics, Inc. (RLMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.51 with +1.56% on the session and $682.8M in market capitalization; recent performance reads 1-month -4.27% and YTD +39.34%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.1M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.7%.
The latest indexable market news headline is "Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.50; recent insider activity includes Shenouda Maged filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.66
P/S
0.00
EV/EBITDA
-8.22
DCF Value
$0.05
FCF Yield
-8.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-71.2%
ROA
-25.0%
ROIC
-27.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.1M | $-0.22 |
| Q4 2025 | $0.00 | $-19.9M | $-0.29 |
| FY 2025 | $0.00 | $-57.4M | $-1.45 |
| Q3 2025 | $0.00 | $-10.1M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.75
Target (Median)
$9.50
Target Range
$8.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.39
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS) and other disorders. The company's primary drug candidate is Esmethadone (also known as d-methadone, dextromethadone, or REL-1017), a novel chemical compound. This N-methyl-D-aspartate receptor antagonist is currently undergoing Phase 3 clinical trials, investigating its efficacy as both a supplementary and standalone treatment for major depressive disorder in adult patients. Founded in 2004, the enterprise maintains its corporate headquarters in Coral Gables, Florida.